Fibrogen Stock Investor Sentiment
| FGEN Stock | USD 1.15 0.02 1.71% |
About 81 percent of FibroGen's investors are selling. The analysis of the overall investor sentiment regarding FibroGen suggests that quite a few traders are terrified. FibroGen's investor sentiment overview provides quick insight into current market opportunities from investing in FibroGen. The current market sentiment, together with FibroGen's historical and current headlines, can help investors time the market. In addition, many technical investors use FibroGen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
FibroGen stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of FibroGen daily returns and investor perception about the current price of FibroGen as well as its diversification or hedging effects on your existing portfolios.
FibroGen |
FibroGen Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards FibroGen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about FibroGen that are available to investors today. That information is available publicly through FibroGen media outlets and privately through word of mouth or via FibroGen internal channels. However, regardless of the origin, that massive amount of FibroGen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of FibroGen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of FibroGen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to FibroGen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive FibroGen alpha.
FibroGen Performance against NYSE Composite
Price Growth (%) |
| Timeline |
1 | Exercise or conversion by K Yu of 3750 shares of FibroGen subject to Rule 16b-3 | 02/23/2024 |
2 | Disposition of 23168 shares by Christine Chung of FibroGen at 1.87 subject to Rule 16b-3 | 03/06/2024 |
3 | FibroGen appoints Deyaa Adib as Chief Medical Officer | 03/11/2024 |
4 | Geron Gets ODAC Votes for Blood Disorder Drug, Shares Up | 03/15/2024 |
5 | Fennec Signs Licensing Deal With Norgine, Stock Up | 03/19/2024 |
6 | Cardiff Stock Rallies 194 percent in a Month Heres Why | 03/21/2024 |
7 | FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference | 03/26/2024 |
8 | Akebia Up as Vafseo Gets FDA Nod for Anemia Due to CKD | 03/28/2024 |
9 | FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers | 04/03/2024 |
10 | Ocugen Up as DSMB Allows Cohort 2 Dosing in GA Study | 04/08/2024 |
11 | Is Entera Bio Outperforming Other Medical Stocks This Year | 04/12/2024 |
12 | Acquisition by Juan Graham of 120000 shares of FibroGen subject to Rule 16b-3 | 04/15/2024 |
13 | Ultragenyx Meets Efficacy Goal in Neuro Disease Study | 04/16/2024 |
14 | Bio-Path Rises on Upbeat Updates From Blood Cancer Study | 04/19/2024 |
Check out FibroGen Hype Analysis, FibroGen Correlation and FibroGen Performance. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for FibroGen Stock analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (2.92) | Revenue Per Share 1.518 | Quarterly Revenue Growth (0.21) | Return On Assets (0.36) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.